ESR1 and breast cancer: Furthermore, miR-17-5p is down-regulated in breast cancer cell lines, which has been shown to limit the oncogene AIB1, which enhances the transcriptional activity of the estrogen receptor (ER) and E2F1, leading to proliferation suppression (44).